Advertisement

Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study

  • Nuggehally R. SrinivasEmail author
Letter to the Editor

Cinacalcet hydrochloride (Sensipar®) has been approved for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients [1, 2]. Due to the efficient targeting of calcium sensory receptors present in parathyroid glands, the pharmacodynamic activity elicited by cinacalcet directly leads to the lowering of serum parathyroid hormone (PTH) and reduced serum levels of both calcium and phosphorous [2]. Despite beneficial effects of cinacalcet therapy in CKD patients pertaining to delayed onset of cardiovascular events, gastrointestinal tolerability issues such as nausea and vomiting have been reported [1, 2, 3]. Another drawback of cinacalcet therapy is with regards to cinacalcet being a perpetrator drug for cytochrome P450 (CYP) 2D6 and a victim drug especially for CYP3A4 [4, 5, 6]. In other words, the CYP profile of cinacalcet suggests that it may precipitate the occurrence of potential drug–drug interactions of substrates and inhibitors of CYP2D6 (i.e....

Notes

Compliance with Ethical Standards

Funding

No funding was received to prepare this letter.

Conflict of Interest

The author has no conflict of interest to declare in the contents of the manuscript, which was solely prepared to exchange clinical pharmacology-related thoughts on a topic of considerable interest.

References

  1. 1.
    Sensipar® (cinacalcet) tablets. Highlights of prescribing information. Amgen, initial approval 2004. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021688s017lbl.pdf. Accessed 8 Oct 2018.
  2. 2.
    Torres PU. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr. 2006;16(3):253–8.CrossRefGoogle Scholar
  3. 3.
    Stubbs JR, Wetmore JB. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? Semin Dial. 2011;24:298–306.CrossRefGoogle Scholar
  4. 4.
    Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303–11.CrossRefGoogle Scholar
  5. 5.
    Harris RZ, Salfi M, Posvar E, Hoelscher D, Padhi D. Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007;63(2):159–63.CrossRefGoogle Scholar
  6. 6.
    Harris RZ, Salfi M, Sullivan JT, Padhi D. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet. 2007;46(6):495–501.CrossRefGoogle Scholar
  7. 7.
    Nakashima D, Takama H, Ogasawara Y, Kawakami T, Nishitoba T, Hoshi S, et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J Clin Pharmacol. 2007;47(10):1311–9.CrossRefGoogle Scholar
  8. 8.
    Akizawa T, Shimazaki R, Shiramoto M, Fukagawa M, Evocalcet Study Group. Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human phase I study. Clin Drug Investig. 2018;38(10):945–54.CrossRefGoogle Scholar
  9. 9.
    Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs. 2005;65(2):271–81.CrossRefGoogle Scholar
  10. 10.
    Narushima K, Maeda H, Shiramoto M, Endo Y, Ohtsuka S, Nakamura H, et al. Assessment of CYP-mediated drug interactions for evocalcet, a new calcimimetic agent, based on in vitro investigations and a cocktail study in humans. Clin Transl Sci. 2018.  https://doi.org/10.1111/cts.12588.CrossRefPubMedGoogle Scholar
  11. 11.
    Shigematsu T, Shimazaki R, Fukagawa M, Akizawa T. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. Clin Pharmacol. 2018;11(10):101–11.  https://doi.org/10.2147/CPAA.S171044.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Zydus Research Centre, a Division of Cadila Healthcare LtdAhmedabadIndia
  2. 2.Jubilant Life Sciences, Innovation and TechnologyNoidaIndia

Personalised recommendations